“The home-grown vaccine, branded Covifenz, is based on a technology that uses plants in its development process to produce non-infectious particles that mimic the virus. It also uses recombinant technology, involving the genetic sequence of a virus, which employs living plants as a host.
Canadian regulators said on Feb. 24 that Medicago’s two-dose vaccine is approved for adults aged 18 to 64.”
The shot was jointly developed by Medicago, a Quebec City-based biopharma company owned by Mitsubishi Chemical and Philip Morris International, and Glaxo, the British pharma giant.
The approval gives people who might be hesitant to take currently available vaccines made by Pfizer, AstraZeneca, Moderna and others another option.